Condition: Relapsed/Refractory Acute Myeloid Leukaemia · Myeloid Malignancy · Sponsor: Ascentage Pharma Group Inc.
The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
This description comes directly from the study's public registry record.
Jie Jin, M.D. · +86 571-87236896 · jiej0503@163.com
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guandong, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Henan Tumor Hospital | Zhengzhou, Henan, China | Recruiting |
| Union Hospital medical college Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Zhongnan Hospital of Hunan university | Wuhan, Hubei, China | Recruiting |
| Xiangya Hospital Central South University | Changsha, Hunan, China | Recruiting |
| The First affiliated hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| Shanghai The Sixth People' s Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| the First Affiliated Hospital, College of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04501120